Description: Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Home Page: www.cullinanoncology.com
CGEM Technical Analysis
One Main Street
Cambridge,
MA
02142
United States
Phone:
617 410 4650
Officers
Name | Title |
---|---|
Mr. Nadim Ahmed | Pres, CEO & Director |
Mr. Jeffrey Trigilio | CFO & Treasurer |
Dr. Patrick A. Baeuerle Ph.D. | Chief Scientific Officer |
Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corp. Sec. |
Ms. Rose Weldon | VP of Communications |
Mr. Steve Andre | Chief HR Officer |
Dr. Corinne Savill Ph.D. | Chief Bus. Officer |
Dr. Jennifer Michaelson Ph.D. | Chief Devel. Officer |
Ms. Kerry Whalen | Sr. Director of Preclinical & Early Devel. |
Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Forward PE: | 6.3012 |
---|---|
Trailing PE: | 4.6853 |
Price-to-Book MRQ: | 0.9098 |
Price-to-Sales TTM: | 26.8794 |
IPO Date: | 2021-01-08 |
Fiscal Year End: | December |
Full Time Employees: | 31 |